- Home
- IOVA vs PRME Comparison
IOVA vs PRME Comparison
Compare IOVA & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- PRME
- Stock Information
- Founded
- IOVA 2007
- PRME 2019
- Country
- IOVA United States
- PRME United States
- Employees
- IOVA N/A
- PRME N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- PRME Medicinal Chemicals and Botanical Products
- Sector
- IOVA Health Care
- PRME Health Care
- Exchange
- IOVA Nasdaq
- PRME Nasdaq
- Market Cap
- IOVA 771.4M
- PRME 191.7M
- IPO Year
- IOVA N/A
- PRME 2022
- Fundamental
- Price
- IOVA $2.31
- PRME $4.12
- Analyst Decision
- IOVA Buy
- PRME Buy
- Analyst Count
- IOVA 10
- PRME 6
- Target Price
- IOVA $12.22
- PRME $9.38
- AVG Volume (30 Days)
- IOVA 13.9M
- PRME 5.7M
- Earning Date
- IOVA 08-07-2025
- PRME 08-04-2025
- Dividend Yield
- IOVA N/A
- PRME N/A
- EPS Growth
- IOVA N/A
- PRME N/A
- EPS
- IOVA N/A
- PRME N/A
- Revenue
- IOVA $212,679,000.00
- PRME $3,846,000.00
- Revenue This Year
- IOVA $86.62
- PRME $104.12
- Revenue Next Year
- IOVA $69.95
- PRME $108.24
- P/E Ratio
- IOVA N/A
- PRME N/A
- Revenue Growth
- IOVA 11070.12
- PRME 550.76
- 52 Week Low
- IOVA $1.64
- PRME $1.11
- 52 Week High
- IOVA $12.51
- PRME $6.40
- Technical
- Relative Strength Index (RSI)
- IOVA 65.80
- PRME 63.41
- Support Level
- IOVA $1.70
- PRME $3.71
- Resistance Level
- IOVA $2.50
- PRME $5.00
- Average True Range (ATR)
- IOVA 0.16
- PRME 0.52
- MACD
- IOVA 0.08
- PRME -0.00
- Stochastic Oscillator
- IOVA 89.16
- PRME 63.58
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.